In this study, we developed a novel in situ strategy combining FDA-approved karyotypic CEP8-FISH and simultaneous phenotypic immunofluorescent staining of tumor biomarkers with either intracellular or extracellular antigenic epitopes (such as HER2 [30], CK, EpCAM, CD133, Vimentin, CD44V6, etc.)as well as CD45 on the identical cells to successfully identify non-hematopoietic, heteroploid tumor cells. This evidence concerns the gene PROM1 and neoplasm.